US Patent 9,220,707: Patent Landscape Analysis for Velcade (Bortezomib)

US Patent 9,220,707, granted on December 29, 2015, to Millennium Pharmaceuticals, Inc., covers a formulation of bortezomib, the active pharmaceutical ingredient in the drug Velcade. This patent is critical for understanding the extended market exclusivity of Velcade, a proteasome inhibitor used in the treatment of multiple myeloma and mantle cell lymphoma. The patent claims a specific lyophilized composition and its methods of preparation and use.

What is the Core Technology Protected by US Patent 9,220,707?

The central innovation claimed by US Patent 9,220,707 is a lyophilized (freeze-dried) composition of bortezomib that enhances its stability and ease of administration. The patent specifically addresses challenges associated with the inherent instability of bortezomib in aqueous solutions. Prior art formulations often required reconstitution immediately before administration and had a limited shelf life once reconstituted.

The '707 patent claims a lyophilized cake comprising:

Bortezomib
A bulking agent, such as mannitol
A buffering agent, such as sodium phosphate (dibasic)
A tonicity adjuster, such as sodium chloride

The composition is designed to be reconstituted with a specific diluent (e.g., sterile water for injection or 0.9% sodium chloride injection) shortly before intravenous or subcutaneous administration. The formulation aims to provide a stable solid dosage form that, upon reconstitution, yields a solution suitable for therapeutic use with improved stability characteristics compared to pre-dissolved solutions.

The key claims within the patent define:

Claim 1: A lyophilized cake comprising bortezomib, a bulking agent, a buffering agent, and a tonicity adjuster.
Claim 2-10: Variations and specifics of the components mentioned in Claim 1, including particular ranges for each component and preferred agents (e.g., mannitol as bulking agent, sodium phosphate as buffering agent, sodium chloride as tonicity adjuster).
Claim 11-15: Methods of preparing the lyophilized composition, involving steps of dissolving the components, filling vials, lyophilizing the solution, and sealing the vials.
Claim 16-20: Methods of reconstituting the lyophilized composition and administering it to a patient.

These claims effectively protect not only the specific formulation but also the process of creating it and its use in treating specific diseases.

What is the Significance of Bortezomib and Velcade?

Bortezomib, marketed as Velcade, is a first-in-class proteasome inhibitor. It functions by inhibiting the 26S proteasome, a protein complex that degrades unneeded or damaged proteins within cells. In cancer cells, particularly multiple myeloma cells, this inhibition leads to an accumulation of proteins that triggers apoptosis (programmed cell death).

Velcade was first approved by the U.S. Food and Drug Administration (FDA) in 2003 for the treatment of multiple myeloma. Its efficacy in managing this relapsed and refractory hematologic malignancy made it a significant therapeutic advancement. Subsequent approvals expanded its use to include patients with mantle cell lymphoma.

The therapeutic importance of Velcade is underscored by its:

Mechanism of Action: A targeted approach to cancer cell death.
Clinical Efficacy: Demonstrated survival benefits and disease control in specific cancer types.
Market Position: A well-established and widely prescribed oncology drug with significant revenue generation for its developer, Millennium Pharmaceuticals (now Takeda Oncology).

The development of a stable, lyophilized formulation, as protected by US Patent 9,220,707, was crucial for expanding Velcade's accessibility and shelf-life, contributing to its widespread clinical adoption.

What is the Patent Expiration Timeline for US Patent 9,220,707?

US Patent 9,220,707 was granted on December 29, 2015. Under standard U.S. patent law, utility patents are typically granted for a term of 20 years from the earliest U.S. non-provisional filing date.

The earliest U.S. non-provisional filing date for the patent that eventually issued as US Patent 9,220,707 is March 29, 2004 (as a continuation-in-part of earlier applications).

Therefore, the expected expiration date for US Patent 9,220,707 is March 29, 2024.

It is important to note that patent terms can be subject to extensions, such as Patent Term Adjustment (PTA) or Patent Term Extension (PTE) under the Hatch-Waxman Act for pharmaceutical patents. PTE is designed to compensate for delays in patent review by the USPTO and delays in obtaining FDA marketing approval.

A review of USPTO records and publicly available patent litigation databases indicates that US Patent 9,220,707 received a 393-day Patent Term Extension. This extension was granted due to delays encountered during the patent prosecution process.

With the addition of the PTA, the adjusted expiration date for US Patent 9,220,707 is calculated as follows:

Original 20-year term expiration: March 29, 2024
Patent Term Adjustment: +393 days

This results in an effective expiration date of approximately April 12, 2025.

Table 1: Patent Expiration Timeline

Patent Number	Grant Date	Earliest Non-Provisional Filing Date	Original 20-Year Expiration	Patent Term Adjustment (PTA)	Adjusted Expiration Date
US 9,220,707 B2	Dec 29, 2015	Mar 29, 2004	Mar 29, 2024	393 days	April 12, 2025

Source: USPTO Patent Term Calculator, Public Patent Databases.

What is the Scope of Patent Protection for the Velcade Formulation?

The scope of protection for US Patent 9,220,707 is defined by its claims. As noted earlier, the claims cover:

The Lyophilized Composition: This includes the specific combination of bortezomib, bulking agent, buffering agent, and tonicity adjuster. The claims are drafted to cover these components, and variations within the defined ranges, even if different specific chemical entities are used for bulking, buffering, or tonicity adjustment, provided they perform the same function.
Method of Preparation: The patent also protects the process of creating this lyophilized composition. This means that any entity manufacturing the formulation using the claimed steps would infringe the patent.
Method of Reconstitution and Administration: The patent claims cover the act of reconstituting the lyophilized product and administering it to a patient for treating specific conditions like multiple myeloma and mantle cell lymphoma.

The scope is broad enough to capture the final drug product and its associated manufacturing and use. However, it is specifically tied to the lyophilized form and its preparation, not necessarily to the bortezomib molecule itself, which is likely covered by earlier, composition-of-matter patents.

What is the Patent Landscape for Bortezomib?

The patent landscape for bortezomib is complex, involving multiple patents covering different aspects of the drug, including the active pharmaceutical ingredient (API), various formulations, methods of treatment, and manufacturing processes.

Key Patents and Their Contributions:

Composition of Matter Patents: The original patents covering the bortezomib molecule itself have long expired. These were foundational and provided initial market exclusivity.
Formulation Patents: US Patent 9,220,707 is a key example of a formulation patent that extends market protection by protecting a specific, improved dosage form. Other formulation patents might cover liquid formulations or other novel delivery systems.
Method of Treatment Patents: Patents may cover specific dosing regimens, combinations with other drugs, or treatment of particular patient populations.
Manufacturing Process Patents: Patents can protect novel or improved methods of synthesizing the bortezomib API or manufacturing its dosage forms.

Impact of Generic Competition:

The expiration of core composition-of-matter patents typically opens the door for generic manufacturers. However, the presence of strong formulation patents, like US 9,220,707, can create "patent thickets" that delay or prevent generic entry. Generic companies must navigate these patents and either challenge their validity, design around them, or wait for their expiration.

In the case of Velcade, the '707 patent provided a significant layer of protection against generic versions of the lyophilized formulation beyond the expiration of the original API patents. Generic manufacturers seeking to launch a bortezomib product would need to consider the claims of this patent carefully.

How Does US Patent 9,220,707 Interact with Other Bortezomib Patents?

US Patent 9,220,707 operates within a broader patent portfolio for Velcade. Its interaction with other patents is critical for determining the overall duration of market exclusivity and the potential for generic competition.

Foundation of Original Patents: The earliest patents for bortezomib covered the chemical entity itself. These have expired, allowing for the possibility of generic versions of the API.
Fortification by Formulation Patents: Patents like 9,220,707 were strategically filed to protect improvements and specific forms of the drug. This particular patent focuses on the lyophilized product, which was a significant commercial formulation.
Blocking Generic Entry: Generic versions of Velcade that aim to replicate the lyophilized formulation protected by this patent would likely infringe its claims. Generic companies might attempt to:
- Challenge the validity of the '707 patent.
- Develop a different formulation (e.g., a liquid formulation not covered by the claims, or a different lyophilized composition that avoids infringing specific claims).
- Obtain a license from the patent holder.
- Wait for the patent to expire.
Litigation: The '707 patent has been a subject of patent litigation, as is common for key patents protecting blockbuster drugs. Such litigation often involves challenges to patent validity or arguments of non-infringement by generic competitors. For instance, challenges could focus on whether the generic product falls within the literal scope of the claims or if the claims are invalid due to obviousness or lack of novelty.

The interplay between the '707 patent and other existing patents influences the competitive landscape and pricing strategies for bortezomib therapies.

What are the Implications for Generic Manufacturers?

For generic manufacturers aiming to enter the bortezomib market, US Patent 9,220,707 presents significant considerations:

Product Design and Formulation: Generic companies must meticulously design their products to avoid infringing the claims of the '707 patent. This may involve:
- Developing a non-lyophilized formulation.
- Using different excipients or ratios that fall outside the patent's defined claims.
- Employing a manufacturing process that does not replicate the patented methods.
- If a lyophilized formulation is intended, careful analysis of each claim element is required to ensure non-infringement.
Patent Litigation Risk: Attempting to market a product that is perceived to infringe the '707 patent carries a high risk of litigation. Patent holders actively defend their intellectual property, leading to potentially costly legal battles. Generic companies must assess the strength of the patent and the likelihood of success in a validity challenge or non-infringement defense.
Freedom to Operate (FTO) Analysis: A comprehensive FTO analysis is essential. This involves identifying all relevant patents, including the '707 patent, and assessing whether a proposed generic product can be marketed without infringing any valid and enforceable patent rights.
Timing of Market Entry: The adjusted expiration date of April 12, 2025, for US Patent 9,220,707 dictates when generic manufacturers can freely market a lyophilized bortezomib formulation that falls within the patent's scope. Before this date, any such product is subject to potential infringement claims.
Alternative Formulations: Generic manufacturers may focus on developing and launching formulations that are not covered by the '707 patent, such as liquid formulations or different solid dosage forms, if such alternatives exist and are commercially viable.

The '707 patent's expiration, with its PTA, provides a clear timeline for when the protected lyophilized formulation will become available for generic replication.

What are the Potential Business Implications for Velcade's Innovator?

For Millennium Pharmaceuticals (Takeda Oncology), the primary innovator of Velcade, US Patent 9,220,707 has provided a crucial extension of market exclusivity for a highly successful product. The business implications include:

Sustained Revenue: The patent has allowed for continued sales of the proprietary lyophilized Velcade formulation, generating significant revenue streams and allowing the company to recoup R&D investments and fund further pipeline development.
Competitive Barrier: The patent has served as a significant barrier to entry for generic competitors seeking to market a direct equivalent of the lyophilized Velcade product. This has helped maintain Velcade's market share and pricing power.
Strategic Lifecycle Management: The '707 patent exemplifies a successful strategy of lifecycle management for a blockbuster drug. By securing patents on improved formulations, companies can extend the commercial life of a product beyond the expiration of its initial composition-of-matter patents.
Negotiating Leverage: The patent provides negotiating leverage in discussions with potential generic manufacturers, potentially leading to lucrative settlement agreements or licensing deals that include a period of delayed generic entry in exchange for a share of future revenues.
Focus on Next-Generation Therapies: The revenue and market position secured by such patents allow the innovator company to focus R&D efforts on developing next-generation therapies and expanding their oncology portfolio.

The expiration of this patent will mark a significant shift, leading to increased competition and potential price erosion for the lyophilized Velcade formulation.

Key Takeaways

US Patent 9,220,707 protects a lyophilized formulation of bortezomib, enhancing its stability and usability. The patent's claims cover the specific composition, its preparation, and methods of administration. This patent was crucial for extending Velcade's market exclusivity beyond the expiration of the original composition-of-matter patents. The patent is set to expire around April 12, 2025, after accounting for Patent Term Adjustment. Generic manufacturers must carefully navigate this patent's scope, and its expiration will significantly impact the Velcade market by enabling generic entry of the protected formulation. The innovator company has benefited from sustained revenue and competitive advantage due to this formulation patent.

Frequently Asked Questions

What is the primary function of the bulking agent in the '707 patent's formulation? The bulking agent, such as mannitol, provides structural support to the lyophilized cake, preventing its collapse during the freeze-drying process and ensuring a porous structure that facilitates reconstitution.
Can a company sell a bortezomib product that is not lyophilized before US Patent 9,220,707 expires? Yes, if the non-lyophilized formulation does not infringe any other valid and enforceable patents covering bortezomib. US Patent 9,220,707 specifically protects the lyophilized composition and its related methods.
What happens if a generic company uses bortezomib and excipients within the general ranges claimed by US Patent 9,220,707 but calls it a different product name? The product name is irrelevant to patent infringement. If the composition and methods used by the generic company fall within the scope of the patent's claims, it would constitute infringement, regardless of the product's trade name.
How does the Patent Term Adjustment (PTA) for US Patent 9,220,707 impact its expiration date? The PTA is an addition to the standard 20-year patent term, compensating for delays in prosecution at the USPTO. In this case, the 393-day PTA extended the expiration date from March 29, 2024, to approximately April 12, 2025, delaying the period for unrestricted generic market entry of the protected formulation.
Does the expiration of US Patent 9,220,707 mean all bortezomib patents have expired? No, the expiration of US Patent 9,220,707 pertains specifically to the claims covering its particular lyophilized formulation and associated methods. Other patents related to bortezomib, such as those covering different formulations, manufacturing processes, or methods of treatment, may still be in effect or have different expiration dates.

Citations

[1] Millennium Pharmaceuticals, Inc. (2015). Lyophilized compositions of bortezomib and methods of preparation and use thereof (U.S. Patent No. 9,220,707). United States Patent and Trademark Office.

[2] U.S. Food and Drug Administration. (n.d.). Drug Search for Velcade. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?action=evidence.drugDetails&DrugNameID=1950

[3] United States Patent and Trademark Office. (n.d.). Patent Term Calculator. Retrieved from https://tool.uspto.gov/twp/ (Note: Specific calculations for PTA require access to detailed USPTO records or specialized patent databases).

[4] Various patent litigation databases and summaries (e.g., Docket Navigator, Lex Machina) for information on patent challenges and litigation related to bortezomib patents. (Specific URL not provided as this refers to a type of resource.)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Botanix Sb	SOFDRA	sofpironium bromide	GEL, METERED;TOPICAL	217347-001	Jun 18, 2024		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				TOPICAL TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014227923	⤷ Start Trial
Brazil	112015023153	⤷ Start Trial
Canada	2904724	⤷ Start Trial
China	105050596	⤷ Start Trial
China	109364066	⤷ Start Trial
Denmark	2968267	⤷ Start Trial
European Patent Office	2968267	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,220,707

Which drugs does patent 9,220,707 protect, and when does it expire?

Summary for Patent: 9,220,707